CNTX Insider Trading

Insider Ownership Percentage: 6.66%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Context Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Context Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Context Therapeutics Share Price & Price History

Current Price: $1.38
Price Change: Price Increase of +0.08 (6.15%)
As of 04/25/2024 01:00 AM ET

This chart shows the closing price history over time for CNTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Context Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/21/2023Martin A. LehrCEOBuy5,823$0.84$4,891.32159,701View SEC Filing Icon  
2/13/2023Martin A. LehrCEOBuy5,606$0.87$4,877.22153,878View SEC Filing Icon  
2/6/2023Martin A. LehrCEOBuy5,040$0.97$4,888.80148,272View SEC Filing Icon  
1/30/2023Martin A. LehrCEOBuy7,027$0.70$4,918.90143,232View SEC Filing Icon  
1/23/2023Martin A. LehrCEOBuy6,839$0.72$4,924.08136,205View SEC Filing Icon  
1/17/2023Martin A. LehrCEOBuy6,783$0.74$5,019.42129,366View SEC Filing Icon  
12/16/2022Jennifer Lynn Minai-AzaryCFOBuy25,000$0.74$18,500.0040,000View SEC Filing Icon  
12/9/2022Alex C. LevitInsiderBuy6,000$0.85$5,100.009,000View SEC Filing Icon  
8/19/2022Martin A. LehrCEOBuy13,000$1.85$24,050.00102,583View SEC Filing Icon  
12/16/2021Martin A. LehrCEOBuy13,000$3.22$41,860.00View SEC Filing Icon  
10/22/2021Alex C. LevitInsiderBuy3,000$5.00$15,000.00View SEC Filing Icon  
10/22/2021Martin A. LehrCEOBuy10,000$5.00$50,000.00View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Context Therapeutics (NASDAQ:CNTX)

14.03% of Context Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CNTX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Context Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/15/2024Opaleye Management Inc.975,000$1.10M0.3%N/A6.107%Search for SEC Filing on Google Icon
11/15/2023Affinity Asset Advisors LLC328,817$0.50M0.1%+22.9%2.059%Search for SEC Filing on Google Icon
8/21/2023Affinity Asset Advisors LLC267,574$0.43M0.1%N/A1.675%Search for SEC Filing on Google Icon
7/21/2023Clear Harbor Asset Management LLC36,000$58K0.0%N/A0.225%Search for SEC Filing on Google Icon
2/16/2023AIGH Capital Management LLC1,143,745$0.75M0.2%-11.5%7.162%Search for SEC Filing on Google Icon
2/14/2023swisspartners Ltd.180,000$0.12M0.2%+111.8%1.127%Search for SEC Filing on Google Icon
11/14/2022Worth Venture Partners LLC322,628$0.36M0.2%+8.4%2.021%Search for SEC Filing on Google Icon
11/1/2022swisspartners Ltd.85,000$94K0.1%+101.3%0.532%Search for SEC Filing on Google Icon
8/13/2022Virtu Financial LLC46,445$98K0.0%N/A0.291%Search for SEC Filing on Google Icon
8/12/2022Affinity Asset Advisors LLC883,654$1.87M0.8%+13.6%5.535%Search for SEC Filing on Google Icon
5/4/2022swisspartners Ltd.14,315$4.98M3.5%-66.1%0.090%Search for SEC Filing on Google Icon
2/14/2022Altium Capital Management LP493,531$1.31M0.4%N/A4.501%Search for SEC Filing on Google Icon
2/11/2022QCM Cayman Ltd.14,041$37K0.2%N/A0.128%Search for SEC Filing on Google Icon
2/10/2022AIGH Capital Management LLC762,721$2.03M0.6%N/A6.955%Search for SEC Filing on Google Icon
2/9/2022swisspartners Ltd.42,235$0.11M0.1%N/A0.385%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Context Therapeutics logo
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Read More on Context Therapeutics

Today's Range

Now: $1.38
Low: $1.32
High: $1.38

50 Day Range

MA: $1.24
Low: $1.04
High: $1.52

52 Week Range

Now: $1.38
Low: $0.47
High: $1.69

Volume

27,159 shs

Average Volume

51,659 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.17

Who are the company insiders with the largest holdings of Context Therapeutics?

Context Therapeutics' top insider shareholders include:
  1. Martin A Lehr (CEO)
  2. Jennifer Lynn Minai-Azary (CFO)
  3. Alex C Levit (Insider)
Learn More about top insider investors at Context Therapeutics.